Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.52 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | QDPR | P09417 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18324892 | 0.91 | MAPT (0.52) | MAPTLMNA | |
| SCHEMBL16801502 | 0.85 | MAPT (0.59) | MAPTTDO2LMNAPOLBTP53 | |
| SCHEMBL16801678 | 0.83 | SLC6A4 (0.56) | MAPTHTR1DTDO2LMNAPOLB | |
| SCHEMBL7867998 | 0.83 | SLC6A4 (0.63) | LMNAPOLB | |
| SCHEMBL21758836 | 0.83 | MAPT (0.45) | MAPTHTR1DTDO2LMNAPOLB | |
| SCHEMBL16801665 | 0.81 | SLC6A4 (0.59) | MAPTTDO2LMNAPOLBTP53 | |
| SCHEMBL18324766 | 0.81 | SLC6A4 (0.49) | MAPTTDO2LMNAPOLBQDPR | |
| SCHEMBL18324806 | 0.80 | TDO2 (0.67) | MAPTHTR1DTDO2LMNAPOLB | |
| SCHEMBL11864713 | 0.80 | LMNA (0.66) | MAPTTDO2LMNAPOLBTP53 | |
| SCHEMBL16801687 | 0.79 | SLC6A4 (0.69) | TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3082802-B1 | TRYPTOPHAN-2,3-DIOXYGENASE (TDO) AND/OR INDOLAMINE-2,3-DIOXYGENASE (IDO) INHIBITORS AND THEIR USE | IOMET PHARMA LTD (GB) | 2020-02-26 | — | — | EP | disclosed |
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367564-A1 | Pharmaceutical Compound | TDO2, IDO1, IDO2 | MAPT 2964/4885HTR1D 225/4885TDO2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.